This flash is about the classification fight — drug path vs biologic path — not whether the molecule works or is approved. The Seventh Circuit heard argument, took the case under advisement, and ordered jurisdiction memos. Argument day is not a ruling.
Peptide Straight Talk editorial desk · as of September 24, 2026
Between Issue #1 and Issue #2 — classification law, not a full peptide deep-dive. Not medical advice.
Taxonomy: COURT = opinion/filing · REG-AUTH = FDA/federal rule · STATUTE/REG = U.S. Code / CFR
What happened as of Sept. 24, 2026
The U.S. Court of Appeals for the Seventh Circuit heard oral argument in Eli Lilly and Company v. Robert Kennedy, Jr., No. 26-1301, before Chief Judge Brennan and Judges Easterbrook and Kirsch. The case was taken under advisement. The panel also ordered supplemental memoranda on appellate jurisdiction, due October 8, 2026.
No Seventh Circuit opinion has issued. Argument day is not a decision.
Docket check (as of Sept. 24, 2026): CourtListener/RECAP + public calendar — oral argument held and taken under advisement; no Seventh Circuit opinion located.
What people are saying
Around peptide and metabolic Twitter, the shorthand is: “Is retatrutide a biologic?” That label sits next to real regulatory stakes — which approval pathway would apply, what follow-on competition architecture would look like, and whether the statutory compounding exemptions could ever reach a product after biologic licensure.
The talk is loud. The fight underneath is narrower — and more useful.
The clean scoreboard
Decided (district court)
In Lilly v. Kennedy (HHS/FDA officials), S.D. Ind. No. 1:24-cv-01503, the October 3, 2025 amended order and the December 16, 2025 final judgment (the September 30, 2025 summary-judgment order was superseded by the October 3 amendment) held:
Protein reading upheld. FDA’s interpretation — a protein is an alpha amino acid polymer greater than 40 amino acids — stood. The court agreed with FDA’s refusal to call retatrutide a protein.
Designation decision vacated. The March 18, 2024 letter of designation is what FDA originally wrote. It is not the post-judgment operative designation.
“Analogous product” remanded. That piece goes back to FDA.
No ordered biologic designation. The court did not order FDA to classify retatrutide as a biologic.
Post-judgment status: designation vacated; protein upheld; analogous remanded; no ordered biologic.
Pending (Seventh Circuit)
Appeal: No. 26-1301, under advisement after argument on Sept. 24, 2026.
Supplemental jurisdiction memos due October 8, 2026 — docket activity, not a merits holding.
No Seventh Circuit opinion yet.
Live briefed questions include whether all amino acids count toward “greater than 40,” and whether a designation-request statute (21 U.S.C. §360bbb-2) should force Lilly’s requested designation after vacatur. Those are advocated positions — not holdings.
Not decided / not the record
If you saw posts claiming the appeals court already made retatrutide a biologic, or that the district court ordered biologic status — that is not the record. The December 16, 2025 final judgment vacated the designation decision and remanded the analogous-product question; the court upheld FDA’s protein interpretation and did not order biologic status. The March 18, 2024 letter is what FDA originally wrote — not an operative final designation after judgment. The appeal is pending; no Seventh Circuit opinion has issued.
Why the label matters
Classification is not a judgment on whether the molecule “works.” It is a regulatory fork.
If treated as a drug | If treated as a biological product |
|---|---|
Food, Drug, and Cosmetic Act (FDCA) §505 path (new drug application; later possible generics) | Public Health Service (PHS) Act §351 path (biologics license application; later possible biosimilars) |
Follow-on under ordinary drug/generic rules (when applicable) | Biosimilar / interchangeability architecture under the Biologics Price Competition and Innovation Act (BPCIA) |
Different exclusivity design (statute-dependent; exclusivity attaches at approval) | Reference-product exclusivity that can run ~12 years before a biosimilar approval can be made effective (42 U.S.C. §262(k)(7)) — from licensure |
Ordinary drug compounding rules after approval — already tight | Biological products subject to licensure under §351 are outside the statutory compounding exemptions in FDCA §§503A and 503B |
Why Lilly fights, in one sentence: a biologic path can mean ~12-year reference-product exclusivity from licensure and put a §351 biological product outside the 503A/503B compounding exemptions after licensure — pathway-dependent future stakes, not today’s approval.
REG-AUTH: FDA’s March 23, 2020 compounder notice ties that 503A/503B ineligibility to biological products subject to licensure under §351.
Hard clarity: retatrutide is still investigational. Classification ≠ approval. Separately, FDA states that retatrutide cannot currently be used in compounding under federal law (FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss: “Retatrutide and cagrilintide cannot be used in compounding”). That statement does not wait on this appeal. Unapproved status alone is too broad a wall to lean on — compounded drugs themselves are not FDA-approved; the operative limit here is FDA’s specific compounding statement plus the separate §351 / 503A–503B framework.
Why people think biologic fits
The intuition is almost physical. Retatrutide sits near a bright line at roughly forty amino acids. Community shorthand treats “longer = more protein-like = biologic.” Lilly’s Request for Designation (RFD) story, as recited in court, leans into a related count: backbone plus associated residues that, totaled, cross forty.
That belief is not random. It tracks a real wall Congress and FDA built between many synthetic peptide drugs and protein biologics.
Bright line and the record
The bright line (REG-AUTH / STATUTE/REG)
Under the PHS Act, a “biological product” includes a protein or an analogous product (42 U.S.C. §262(i)(1)).
In 2020, FDA finalized a bright-line definition: a protein is an alpha amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size (21 C.F.R. §600.3(h)(6); 85 FR 10057, Feb 21, 2020, effective Mar 23, 2020). FDA’s draft peptide clinical-pharmacology guidance uses the complementary shorthand: for that guidance, a “peptide” is 40 or fewer amino acids and — if it meets the drug definition and not the biologic definition — is regulated as a drug.
Near that line, counting rules are not pedantry. They are the wall.
What Lilly sought, and what FDA originally wrote
Eli Lilly asked FDA to classify investigational retatrutide as a biological product. On March 18, 2024, FDA’s letter of designation said no: retatrutide is a drug, not a biologic — on FDA’s count, at most 40 alpha amino acids plus one non-alpha residue, and only alpha amino acids count. FDA also said it was not “analogous” to a protein under its then-reasoning.
That March 2024 letter is what FDA originally wrote. It is not the post-judgment status of the designation decision.
What the district court decided (COURT)
As scored above: protein upheld; designation vacated; analogous remanded; no ordered biologic — citing the October 3, 2025 amended order and the December 16, 2025 final judgment.
What the case does—and does not—decide
If you see posts claiming the Seventh Circuit “already made retatrutide a biologic,” or that the district court “ordered FDA to classify it as a biologic” — that is not the record. Classification alone does not approve retatrutide for marketing. Everything else about timing, exclusivity calendars, and compounding after a future approval or licensure is still potential and pathway-dependent. No appellate opinion yet is not evidence against peptides. It is an open scoreboard.
Watch next
October 8, 2026 — supplemental jurisdiction memoranda.
A Seventh Circuit opinion in No. 26-1301 (whenever it issues).
FDA’s remand work on “analogous product,” if the appeal does not swallow that piece.
We’ll update when the Seventh Circuit speaks.
Sources (primary)
REG-AUTH — FDA final rule, 85 FR 10057
STATUTE/REG — 21 C.F.R. §600.3
STATUTE/REG — 42 U.S.C. §262
STATUTE/REG — 21 U.S.C. §360bbb-2
REG-AUTH — FDA Notice to Compounders (Mar 23, 2020)
Educational / research framing only. Not medical advice. Not a recommendation to use, compound, buy, or sell any product. Re-check Seventh Circuit docket 26-1301 after an opinion issues.
